Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus
Clinical trial NCT03451422 · COMPLETED
Trial details
- NCT number
- NCT03451422
- Sponsor
- Amgen
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-10
- Primary completion
- 2021-10-12
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.